181 related articles for article (PubMed ID: 38649964)
1. Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune phenotypes.
Pan JW; Ragu M; Chan WQ; Hasan SN; Islam T; Teoh LY; Jamaris S; See MH; Yip CH; Rajadurai P; Looi LM; Taib NAM; Rueda OM; Caldas C; Chin SF; Lim J; Teo SH
Breast Cancer Res; 2024 Apr; 26(1):67. PubMed ID: 38649964
[TBL] [Abstract][Full Text] [Related]
2. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
[TBL] [Abstract][Full Text] [Related]
3. Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients.
Schroth W; Büttner FA; Kandabarau S; Hoppe R; Fritz P; Kumbrink J; Kirchner T; Brauer HA; Ren Y; Henderson D; Madden SF; Sauer G; Fehm T; Wallwiener D; Fasching PA; Mürdter T; Schwab M; Brauch H;
Clin Cancer Res; 2020 Dec; 26(24):6523-6534. PubMed ID: 33008814
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
5. MYC amplification in subtypes of breast cancers in African American women.
Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
[TBL] [Abstract][Full Text] [Related]
6. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
7. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
Su Y; Zheng Y; Zheng W; Gu K; Chen Z; Li G; Cai Q; Lu W; Shu XO
BMC Cancer; 2011 Jul; 11():292. PubMed ID: 21749714
[TBL] [Abstract][Full Text] [Related]
8. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
[TBL] [Abstract][Full Text] [Related]
9. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
10. The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences.
Pan JW; Zabidi MMA; Ng PS; Meng MY; Hasan SN; Sandey B; Sammut SJ; Yip CH; Rajadurai P; Rueda OM; Caldas C; Chin SF; Teo SH
Nat Commun; 2020 Dec; 11(1):6433. PubMed ID: 33353943
[TBL] [Abstract][Full Text] [Related]
11. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.
Ferrari A; Vincent-Salomon A; Pivot X; Sertier AS; Thomas E; Tonon L; Boyault S; Mulugeta E; Treilleux I; MacGrogan G; Arnould L; Kielbassa J; Le Texier V; Blanché H; Deleuze JF; Jacquemier J; Mathieu MC; Penault-Llorca F; Bibeau F; Mariani O; Mannina C; Pierga JY; Trédan O; Bachelot T; Bonnefoi H; Romieu G; Fumoleau P; Delaloge S; Rios M; Ferrero JM; Tarpin C; Bouteille C; Calvo F; Gut IG; Gut M; Martin S; Nik-Zainal S; Stratton MR; Pauporté I; Saintigny P; Birnbaum D; Viari A; Thomas G
Nat Commun; 2016 Jul; 7():12222. PubMed ID: 27406316
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
Deng L; Zhu X; Sun Y; Wang J; Zhong X; Li J; Hu M; Zheng H
Cancer Res Treat; 2019 Jan; 51(1):128-140. PubMed ID: 29540052
[TBL] [Abstract][Full Text] [Related]
13. Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women.
Park C; Yoon KA; Kim J; Park IH; Park SJ; Kim MK; Jang W; Cho SY; Park B; Kong SY; Lee ES
Cancer Sci; 2019 May; 110(5):1760-1770. PubMed ID: 30811755
[TBL] [Abstract][Full Text] [Related]
14. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
15. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
16. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
17. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
[TBL] [Abstract][Full Text] [Related]
18. Establishment of two basal-like breast cancer cell lines with extremely low tumorigenicity from Taiwanese premenopausal women.
Kuo WL; Ueng SH; Wu CH; Lee LY; Lee YS; Yu MC; Chen SC; Yu CC; Tsai CN
Hum Cell; 2018 Apr; 31(2):154-166. PubMed ID: 29484537
[TBL] [Abstract][Full Text] [Related]
19. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
Breast J; 2022; 2022():9238804. PubMed ID: 35711896
[TBL] [Abstract][Full Text] [Related]
20. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures.
Kan Z; Ding Y; Kim J; Jung HH; Chung W; Lal S; Cho S; Fernandez-Banet J; Lee SK; Kim SW; Lee JE; Choi YL; Deng S; Kim JY; Ahn JS; Sha Y; Mu XJ; Nam JY; Im YH; Lee S; Park WY; Nam SJ; Park YH
Nat Commun; 2018 Apr; 9(1):1725. PubMed ID: 29713003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
